Depixus, a pioneer in the field of intereactomics, has been awarded the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at the society’s annual International Conference and Exhibition in Boston, MA. The award was presented to the company for their groundbreaking MAGNA™ technology.
The Ignite Award is given to companies that are revolutionizing the life sciences with their innovative technologies. Depixus was selected as one of just 16 companies to participate in SLAS2024 Innovation AveNEW program, which is a dedicated area for start-ups and emerging companies within the conference. From these 16 companies, eight were chosen as finalists for the Ignite Award.
MAGNA One, based on magnetic force spectroscopy, enables high-throughput analysis of dynamic biomolecular interactions. This technology is the first to offer real-time measurements from thousands of individual molecules simultaneously, making it particularly useful for exploring challenging targets such as RNA and protein-protein interactions. It provides valuable insights into disease mechanisms and accelerates the development of novel therapeutics.
Depixus CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that this recognition coincides with the launch of their technology access program and commercial rollout of MAGNA One, marking a significant moment for Depixus’ growth trajectory.